[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"genito-urinary-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:genito-urinary-cancer":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,45],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100568438","feasibility-study-of-cbct-for-igrt-in-cancer-patients-100568438",false,"NCT06681233","Feasibility Study of CBCT for IGRT in Cancer Patients","A Feasibility Study of a Novel Cone-Beam CT Approach for Image Guided Radiotherapy in Cancer Patients","Inclusion Criteria:\n\n1. Patient age ≥ 18\n2. Patient is receiving radiation therapy for head and neck, thorax, liver, breast, genitourinary, or gastrointestinal malignancies\n3. A CBCT acquisition for localization is standard of care for the radiation therapy treatment plan being delivered\n\nExclusion Criteria:\n\n1. Patient has ECOG Performance Status ≥3.\n2. Patient is wheelchair bound.\n3. Patient has a life expectancy \\\u003C3 months.\n4. Patient is unwilling or unable to provide informed consent to participate in the study.\n5. Patient is pregnant or has plans for pregnancy during the period of treatment.\n6. Patient is part of a vulnerable population (per ISO 14155:2020, \"individuals who are unable to fully understand all aspects of the investigation that are relevant to the decision to participate, or who could be manipulated or unduly influenced as a result of a compromised position, expectation of benefits or fear of retaliatory response\"). This includes prisoners.","ALL","18 Years",{"count":19,"type":20},50,"ESTIMATED","INTERVENTIONAL",[23],"NA","Cone beam computed tomography (CBCT) is an imaging technology that is incorporated into many modern radiation therapy systems. The quality of conventional CBCT is good enough to align patients for their daily radiation therapy but CBCT images have poor contrast and are susceptible to imaging artefacts that limit their usability for other tasks in the radiation therapy workflow.\n\nVarian Medical Systems, the sponsor of this study, has developed new CBCT imaging technology called HyperSight that so far has demonstrated increased image quality compared with conventional CBCT images. This new HyperSight CBCT imager has previously been built into Varian Halcyon and Ethos treatment machines, where the imager is enclosed in a ring that rotates around the patient. Now, HyperSight has been built into a Varian treatment machine, called TrueBeam, where the imager is mounted on a C-shaped arm that rotates around you to acquire an image.\n\nThis study is being done to evaluate the image quality of HyperSight CBCT compared to conventional CBCT images, and to determine whether HyperSight CBCT can improve the process of delivering radiation treatments.\n\nThe goal of this study is to collect images from this new HyperSight-TrueBeam CBCT imager from a variety of patients and locations in the body. The images will be analyzed to determine whether their quality is high enough to use for tasks other than positioning patients for treatment. For example, the study will determine whether the HyperSight images could be used to calculate a radiation plan.",[26,27,28,29,30,31],"Head and Neck Cancers","Breast Cancer","Thoracic Cancers","Liver Cancer","Genito Urinary Cancer","Gastrointestinal Cancers","RECRUITING","2026-03-12",{"date":35,"type":36},"2026-03-13","ACTUAL",{"date":38,"type":36},"2025-02-19",{"date":40,"type":20},"2026-09",{"name":42,"class":43},"Varian, a Siemens Healthineers Company","INDUSTRY",4,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":52,"minAge":17,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":21,"phases":56,"briefSummary":58,"conditions":59,"keywords":62,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":5},"100571243","phase-3-low-intensity-extracorporeal-shockwave-therapy-on-penile-rehabilitation-after-robot-assisted-surgical-treatment-of-genitourinary-cancers-100571243","NCT06717711","Low-Intensity Extracorporeal Shockwave Therapy on Penile Rehabilitation After Robot-assisted Surgical Treatment of Genitourinary Cancers","RCT_LiESWT","Inclusion Criteria:\n\n* Patients aged ≤75 yrs;\n* PSA \\\u003C10 ng\u002FmL\n* Prostate Cancer ISUP grade ≤2 and cT≤2 at prostate biopsy\n* undergoing nerve sparing RARP;\n* preoperative IIEF-5 score ≥ 17;\n* First PSA (45d after surgery) \\\u003C0.1\n* Prostate Cancer ISUP grade ≤2 pT\\\u003C3b and at final pathology\n* ≥ 18 yrs old;\n* compliants patients able to follow the study protocol and fill in IIEF-5 scores and EORTC quality of life questionnaires;\n* patients able to provide a written informed consent for the trial.\n\nExclusion Criteria:\n\n* anaesthesiologic contraindications to robotic surgery\n* patients submitted to pelvic radiotherapy or androgen deprivation\n* patients reporting major postoperative complications (CD≥3)\n* cardiovascular contraindications to PDE5i medical treatment","MALE","75 Years",{"count":55,"type":20},158,[57],"PHASE3","This prospective randomized controlled trial (RCT) is designed to provide high level evidence on the efficacy of Low-intensity Extracorporeal Shock Wave Therapy (Li-ESWT) in the treatment of post-Robot-Assisted (RA) Radical Prostatectomy (RP) erectile dysfunction (ED) in addition to PDE5 inhibitors (PDE5i) versus PDE5i alone. Our hypothesis is that early andrological rehabilitation that combines Li-ESWT and PDE5i could lead to faster and better recovery of valid erections for intercourse, with a greater rate of postoperative International Index of Erectile Function-5 (IIEF-5) compared to patients receiving PDE5i alone.",[60,61,30],"Prostate Carcinoma","Erectile Function",[63,64,65,66],"prostate cancer","erectile function","rehabilitation","genitourinary cancers","2024-11-30",{"date":69,"type":36},"2024-12-05",{"date":71,"type":36},"2024-08-31",{"date":73,"type":20},"2026-08-31",{"name":75,"class":76},"Regina Elena Cancer Institute","OTHER"]